494 related articles for article (PubMed ID: 32008738)
21. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients.
Grynberg M; Poulain M; le Parco S; Sifer C; Fanchin R; Frydman N
Hum Reprod; 2016 Mar; 31(3):623-9. PubMed ID: 26759139
[TBL] [Abstract][Full Text] [Related]
22. Fertility preservation in breast cancer patients.
Rodgers RJ
Minerva Ginecol; 2019 Jun; 71(3):196-206. PubMed ID: 31089071
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy and female fertility.
Sellami I; Beau I; Sonigo C
Ann Endocrinol (Paris); 2023 May; 84(3):382-387. PubMed ID: 36967045
[TBL] [Abstract][Full Text] [Related]
24. [Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors].
Dadoun Y; Azaïs H; Keller L; d'Orazio E; Collinet P; Decanter C
Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):359-365. PubMed ID: 28506797
[TBL] [Abstract][Full Text] [Related]
25. Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy.
Lambertini M; Ginsburg ES; Partridge AH
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):98-107. PubMed ID: 25490381
[TBL] [Abstract][Full Text] [Related]
26. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response.
Alvarez RM; Ramanathan P
Hum Reprod; 2018 Nov; 33(11):2051-2059. PubMed ID: 27370358
[TBL] [Abstract][Full Text] [Related]
27. [Preservation of fertility in children with cancer].
de Lambert G; Poirot C; Guérin F; Brugières L; Martelli H
Bull Cancer; 2015 May; 102(5):436-42. PubMed ID: 25818928
[TBL] [Abstract][Full Text] [Related]
28. Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer.
Rodriguez-Wallberg KA; Oktay K
Oncologist; 2012; 17(11):1409-17. PubMed ID: 23006497
[TBL] [Abstract][Full Text] [Related]
29. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation.
Sonigo C; Comtet M; Duros S; Sifer C; Sermondade N; Grynberg M
J Assist Reprod Genet; 2018 Jan; 35(1):91-97. PubMed ID: 28986734
[TBL] [Abstract][Full Text] [Related]
30. Techniques for fertility preservation in patients with breast cancer.
Dunn L; Fox KR
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):68-73. PubMed ID: 19125006
[TBL] [Abstract][Full Text] [Related]
31. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation.
Sermondade N; Sonigo C; Sifer C; Valtat S; Ziol M; Eustache F; Grynberg M
Fertil Steril; 2019 Feb; 111(2):357-362. PubMed ID: 30527837
[TBL] [Abstract][Full Text] [Related]
32. Controlled ovarian stimulation outcomes of fertility preservation procedures in newly diagnosed breast cancer patients: a retrospective study from a single-tertiary-IVF centre.
Sahin G; Goker ENT; Gokmen E; Yeniay L; Acet F; Zekioglu O; Tavmergen E
J Obstet Gynaecol; 2022 Apr; 42(3):518-523. PubMed ID: 34382483
[TBL] [Abstract][Full Text] [Related]
33. IVF for fertility preservation in breast cancer patients--efficacy and safety issues.
Shapira M; Raanani H; Meirow D
J Assist Reprod Genet; 2015 Aug; 32(8):1171-8. PubMed ID: 26126877
[TBL] [Abstract][Full Text] [Related]
34. [Oocyte/embryo cryopreservation before chemotherapy for breast cancer].
Decanter C; Gligorov J
Gynecol Obstet Fertil; 2011 Sep; 39(9):501-3. PubMed ID: 21835668
[TBL] [Abstract][Full Text] [Related]
35. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
[TBL] [Abstract][Full Text] [Related]
36. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
Lambertini M; Goldrat O; Ferreira AR; Dechene J; Azim HA; Desir J; Delbaere A; t'Kint de Roodenbeke MD; de Azambuja E; Ignatiadis M; Demeestere I
Ann Oncol; 2018 Jan; 29(1):237-243. PubMed ID: 29045555
[TBL] [Abstract][Full Text] [Related]
37. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
Fatum M; McVeigh E; Child T
Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119
[TBL] [Abstract][Full Text] [Related]
38. Fertility preservation using controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome.
Reichman DE; Davis OK; Zaninovic N; Rosenwaks Z; Goldschlag DE
Fertil Steril; 2012 Nov; 98(5):1225-8. PubMed ID: 22884018
[TBL] [Abstract][Full Text] [Related]
39. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
40. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
